It seems to me EBOS will wipe out anything below 5.75 cents thats no question, (as they have done offmarket purchase after the deal, its likely they will keep on acquiring)
you dont get many chances to invest lower than Billion Dollar strategic investment of $10m AUD, here is one.
The investment of $9.5 million is through a placement of approximately 165m ordinary shares in MedAdvisor at A$0.0575 a share, representing a 44% premium to the last capital raising price of $0.04 in October 2016. In addition, EBOS has also purchased an additional 20 million shares in an off-market transaction.
Once both of these transactions are completed, EBOS will be a significant shareholder in MedAdvisor with a holding of just over 14%, alongside a number of other pharmacists and pharmacy groups who invested into MedAdvisor in prior capital raisings.
The investment will be used to accelerate MedAdvisor’s customer acquisition strategy through the hospital and GP channels, to broaden the health services made available to pharmacies and their customers via MedAdvisor’s software, to increase the pace of international business development efforts in the UK and US and to extend those efforts to the Asia Pacific region, including New Zealand.
EBOS Group Profile
EBOS is a leading marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Group is dual listed on the New Zealand Securities Exchange (NZX) and the Australian Securities Exchange (ASX), with a market capitalisation of more than NZ$2.6 billion and annual revenue of over NZ$7 billion.
For MedAdvisor, EBOS’ diverse interests include both current and prospective customers and partners.
Add to My Watchlist
What is My Watchlist?
